---
document_datetime: 2023-09-21 20:15:01
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/alpivab-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: alpivab-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.4254018
conversion_datetime: 2025-12-30 08:47:03.309683
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Alpivab

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                       | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended no   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| T/0004               | Transfer of Marketing Authorisation                                                                                                                                         | 24/04/2019 Product                  | on 06/06/2019                               | SmPC, Labelling and PL           |           |
| IB/0002/G            | This was an application for a group of variations. B.I.z - Quality change - Active substance - Other variation B.I.b.1.z - Change in the specification parameters Medicinal | 29/01/2019                          | n/a                                         |                                  |           |

<!-- image -->

Medicinal Product no longer authorised

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

|             | and/or limits of an AS, starting material/intermediate/reagent - Other variation   |            |     |                                   |
|-------------|------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10687 | Periodic Safety Update EU Single assessment -                                      | 17/01/2019 | n/a | PRAC Recommendation - maintenance |
| /201806     | peramivir                                                                          |            |     |                                   |

<!-- image -->